Clinical Trials Browser

INDUSTRY × Pharmaceutical Preparations × Clear all

NCT07431216 2026-03-30

A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression

Phase 1/2 Not yet recruiting

Glioblastoma

NCT07364422 2026-01-23

To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer

Phase 1/2 Not yet recruiting

Gastrointestinal

Stomach Neoplasms

NCT06690775 2025-12-23

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

Phase 2 Recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT03401385 2025-10-21

First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms

NCT00547157 2017-03-15

Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Phase 2 Completed

152 enrolled 18 charts

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasms

NCT01544322 2015-06-18

ME-344-001

Phase 1 Completed

Neoplasm Metastasis, Recurrence

NCT01711398 2015-02-12

IP N02

Phase 1/2 Completed

Other solid neoplasm

All Solid Tumors

NCT01558687 2014-02-04

Cilengitide Imaging Trial in Glioblastoma

Phase 1 Terminated

Neoplasms

NCT01401868 2013-06-24

Phase I Dose Escalation Study of the Safety and Pharmacokinetics of ME-143 Single Agent for Refractory Solid Tumors

Phase 1 Completed

Neoplasm Metastasis, Recurrence

NCT00087854 2008-04-23

Study of Individualized Amonafide to Treat Prostate Cancer

Phase 1/2 Completed

Prostatic Neoplasms

NCT00285675 2006-05-31

Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004

Phase 2 Unknown

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms

NCT00035334 2006-02-14

Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis

Phase 2/3 Completed

GastrointestinalGenitourinaryPlasma cell

Amyloidosis, Arthritis, Rheumatoid, Gastrointestinal Diseases, Kidney Diseases, Neoplasm Metastasis, Nephrotic Syndrome, Familial Mediterranean Fever